Drug Pricing Transparency and Accountability Act
USA117th CongressHR-5463| House
| Updated: 10/1/2021
Matthew M. Rosendale
Republican Representative
Montana
Ways and Means Committee, Health Subcommittee, Energy and Commerce Committee
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Drug Pricing Transparency and Accountability Act This bill establishes a two-year moratorium on allowing new, non-rural hospitals and associated child sites to participate in the 340B drug pricing program; during the moratorium, the Department of Health and Human Services must issue regulations with specified program eligibility standards. The bill also requires additional reporting relating to program participation, eligibility, and costs.
View Full TextSuggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Subcommittee on Health.
Health
Administrative law and regulatory proceduresCongressional oversightDepartment of Health and Human ServicesGovernment information and archivesGovernment studies and investigationsHealth facilities and institutionsHealth information and medical recordsHome and outpatient careHospital careMedicaidMedicarePrescription drugsPublic contracts and procurementPublic-private cooperationState and local government operations
Drug Pricing Transparency and Accountability Act
USA117th CongressHR-5463| House
| Updated: 10/1/2021
Drug Pricing Transparency and Accountability Act This bill establishes a two-year moratorium on allowing new, non-rural hospitals and associated child sites to participate in the 340B drug pricing program; during the moratorium, the Department of Health and Human Services must issue regulations with specified program eligibility standards. The bill also requires additional reporting relating to program participation, eligibility, and costs.
View Full TextSuggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Subcommittee on Health.
Matthew M. Rosendale
Republican Representative
Montana
Ways and Means Committee, Health Subcommittee, Energy and Commerce Committee
Health
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Administrative law and regulatory proceduresCongressional oversightDepartment of Health and Human ServicesGovernment information and archivesGovernment studies and investigationsHealth facilities and institutionsHealth information and medical recordsHome and outpatient careHospital careMedicaidMedicarePrescription drugsPublic contracts and procurementPublic-private cooperationState and local government operations